Abstract
Background: Patients (pts) with unresectable melanoma or sarcoma metastases to the liver have a poor prognosis and few therapeutic options. Percutaneous hepatic perfusion (PHP) is a minimally invasive, catheter directed method of isolating the liver, perfusing with high dose chemotherapy with extracorporeal hemofiltration and systemic return via venovenous bypass. A recently completed, randomized, phase III clinical trial has shown promise with a significantly improved hepatic progression free survival (hPFS) in pts with metastatic ocular or cutaneous melanoma to the liver undergoing PHP, [hPFS 8 months] over best alternative care [hPFS 1.6 months], p<0.0001.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
